Apr 27, 2023
|
Data from Lumos Pharma OraGrowtH Trials to be Presented at Annual Pediatric Endocrine Society Meeting (PES)
|
|
Apr 19, 2023
|
Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
|
|
Mar 9, 2023
|
Lumos Pharma to Participate in Oppenheimer’s 33rd Annual Healthcare Conference Held Virtually March 13-15, 2023
|
|
Mar 5, 2023
|
Additional Data on Lumos OraGrowtH Trials Presented at International Meeting of Pediatric Endocrinology
|
|
Mar 1, 2023
|
Lumos Pharma Reports Full Year 2022 Financial Results, Provides Clinical Development Updates
|
|
Feb 28, 2023
|
Lumos Pharma Completes Patient Enrollment in Two Phase 2 OraGrowtH Trials Evaluating Oral LUM-201 in Moderate Idiopathic PGHD
|
|
Feb 15, 2023
|
Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023
|
|
Jan 3, 2023
|
Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023
|
|
Dec 12, 2022
|
KOL Review of Lumos Pharma’s Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients
|
|
Nov 29, 2022
|
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
|
|